Aprea Therapeutics (APRE) announced the appointment of Nadeem Mirza, M.D., M.P.H. as Chief Medical Officer, CMO, of the Company, effective May 1, 2024. Dr. Mirza has been an integral part of the Company’s senior team as a consultant since February, 2023 and will now assume a more central role in leading the Company’s development of its expanding clinical pipeline. His prior experience includes serving as Senior Vice President, Clinical Development at Salarius Pharmaceuticals (SLRX), from 2020 to 2023
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
- Aprea Therapeutics files to sell 4.39M shares of common stock for holders
- Aprea Therapeutics price target raised to $11 from $9 at Wedbush
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Aprea Therapeutics sees cash runway into 3Q25